Kir-Binding Agents and Methods of Use Thereof
AssigneesNovo Nordisk A/S, Innate Pharma
InventorsSoren Berg Padkaer, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjaergaard
Life of this patent
Estimating the term…
Loading patent…
AssigneesNovo Nordisk A/S, Innate Pharma
InventorsSoren Berg Padkaer, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjaergaard
Estimating the term…
The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
An agent that binds or interacts with an extracellular portion of an inhibitory human Killer IgG-like Receptor (KIR), wherein the agent reduces KIR-mediated inhibition of NK cell cytotoxicity without detectably reducing binding between the KIR and an HLA class I-ligand of the KIR.
(canceled)
31-34. (canceled)
The method of claim, wherein the agent competes with an antibody comprising a VH sequence of SEQ ID NO:17 and a VL sequence of SEQ ID NO:18 in binding to at least one of KIR2DL1 and KIR2DL3.
A method of producing an agent capable of neutralizing KIR mediated inhibition of NK cell cytotoxicity by:
A method for producing an antibody or an antibody fragment that is capable of reducing KIR-mediated inhibition of NK cell cytotoxicity, comprising the steps of:
An isolated antibody or antibody fragment competing with an antibody comprising a VH sequence of SEQ ID NO:17 and a VL sequence of SEQ ID NO:18 in binding to at least one of KIR2DL1 and KIR2DL3.
An isolated antibody or antibody fragment competing with an antibody comprising a VH sequence of SEQ ID NO:21 and a VL sequence of SEQ ID NO:18 in binding to at least one of KIR2DL1 and KIR2DL3.
Dependencies are inferred from the claim text.